文献速递神经肿瘤

世界卫生组织2级少突胶质细胞瘤患者的长期随访

Long-term follow up of patients with WHO grade 2 oligodendroglioma.
PubMed 文献 · J Neurooncol · 2023-08-21

该研究在五个斯堪的纳维亚神经外科中心纳入1998至2016年诊断的126例成人WHO 2级少突胶质细胞瘤患者,中位随访12.0年,中位生存17.8年(95%CI 16.0-19.6);多变量分析显示年龄、肿瘤直径和术前功能状态差(KPS<80)与较短生存相关,手术策略与生存无显著关联。

要点

  • 分子定义的少突胶质细胞瘤患者中位生存达17.8年(95%CI 16.0-19.6)。
  • 年龄每增1岁HR 1.05,肿瘤直径每增1毫米HR 1.05,均与较短生存相关。
  • 术前KPS<80者HR 4.47(95%CI 1.70-11.78,p=0.002),与较短生存相关。

核心结论

  • 分子定义的少突胶质细胞瘤患者在人群背景下也表现出较长生存,这对可能引起长期副作用的治疗的最佳时机选择很重要。
  • 高龄、大肿瘤和术前功能差是较短生存的预测因素。
  • 在本研究材料中,手术策略与生存无显著关联。

研究设计与样本

  • 研究纳入五个斯堪的纳维亚神经外科中心1998至2016年诊断的126例成人WHO 2级少突胶质细胞瘤患者,均已知1p19q共缺失且随访时间超过5年,分析生存及可能影响生存的因素。

主要发现

  • 中位随访12.0年,中位生存17.8年(95%CI 16.0-19.6)。
  • 多变量分析中,年龄与较短生存相关(HR 1.05每岁;CI 1.02-1.08,p<0.001)。
  • 肿瘤直径与较短生存相关(HR 1.05每毫米;CI 1.02-1.08,p<0.001)。
  • 术前功能状态差(KPS<80)与较短生存相关(HR 4.47;CI 1.70-11.78,p=0.002)。
  • 在本研究材料中,手术策略与生存无显著关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Since the introduction of the molecular definition of oligodendrogliomas based on isocitrate dehydrogenase (IDH)-status and the 1p19q-codeletion, it has become increasingly evident how this glioma entity differs much from other diffuse lower grade gliomas and stands out with longer survival and often better responsiveness to adjuvant therapy. Therefore, apart from using a molecular oligodendroglioma definition, an extended follow-up time is necessary to understand the nature of this slow growing, yet malignant condition. The aim of this study was to describe the long-term course of the oligodendroglioma disease in a population-based setting and to determine which factors affect outcome in terms of survival. METHODS: All adults with WHO-grade 2 oligodendrogliomas with known 1p19q-codeletion from five Scandinavian neurosurgical centers and with a follow-up time exceeding 5 years, were analyzed regarding survival and factors potentially affecting survival. RESULTS: 126 patients diagnosed between 1998 and 2016 were identified. The median follow-up was 12.0 years, and the median survival was 17.8 years (95% CI 16.0-19.6). Factors associated with shorter survival in multivariable analysis were age (HR 1.05 per year; CI 1.02-1.08, p < 0.001), tumor diameter (HR 1.05 per millimeter; CI 1.02-1.08, p < 0.001) and poor preoperative functional status (KPS < 80) (HR 4.47; CI 1.70-11.78, p = 0.002). In our material, surgical strategy was not associated with survival. CONCLUSION: Individuals with molecularly defined oligodendrogliomas demonstrate long survival, also in a population-based setting. This is important to consider for optimal timing of therapies that may cause long-term side effects. Advanced age, large tumors and poor function before surgery are predictors of shorter survival.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Carstam L, Latini F, Solheim O, et al. Long-term follow up of patients with WHO grade 2 oligodendroglioma. J Neurooncol. 2023. PMID: 37603235. doi:10.1007/s11060-023-04368-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。